{"id":"W2139004759","doi":"10.1093/neuonc/nou160","title":"Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma","year":2014,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; CancerCare Manitoba; Centre Hospitalier Universitaire de Sherbrooke; McGill University; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Temozolomide; Afatinib; Medicine; Internal medicine; Rash; Dacarbazine; Phases of clinical research; Oncology; Clinical endpoint; Adverse effect; Pharmacokinetics; Epidermal growth factor receptor; Pharmacology; Randomized controlled trial; Clinical trial; Chemotherapy; Erlotinib; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000542199,0.0004633275,0.00203956,0.0004639472,0.0001111103,0.00001279531,0.0001791052,0.0001680993,0.00006379199],"category_scores_gemma":[0.0003587152,0.0002528751,0.00009480109,0.0006699277,0.0002206646,0.0001364964,0.00006662901,0.0004227655,0.000006057918],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001573741,"about_ca_system_score_gemma":0.0003405465,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003610513,"about_ca_topic_score_gemma":0.00355929,"domain_scores_codex":[0.9964938,0.0008797398,0.0008502353,0.0008053691,0.00047425,0.0004966564],"domain_scores_gemma":[0.9974149,0.0007494297,0.0005941233,0.0006365124,0.0002670619,0.0003380119],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7952145,0.1163871,0.01213253,0.0001352122,0.0003563661,0.001679515,0.004578075,0.00001681349,0.02337451,0.00000864808,0.000200391,0.04591632],"study_design_scores_gemma":[0.654209,0.3313765,0.001380945,0.0003405534,0.0007603334,0.0002778055,0.001563358,0.001592888,0.007395065,0.000003293617,0.0008648371,0.000235495],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910947,0.00004575309,0.00001135718,0.0004168423,0.0001491873,0.00789445,0.00001851478,0.00009861907,0.0002705667],"genre_scores_gemma":[0.9974186,0.0000303617,0.0008647535,0.0002670976,0.00008703955,0.00120681,0.00004453022,0.00006456755,0.00001620464],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2149894,"threshold_uncertainty_score":0.9999924,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02280740465076383,"score_gpt":0.3333385568777372,"score_spread":0.3105311522269734,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}